Actuate Therapeutics (ACTU): Hexstone Capital LLC now owns 7.7% of ACTU as a passive investor 7.7%

7.7%

Stake

4.23M

Shares owned

Stake as of

Oct 27, 2026

Filed

Oct 30, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 26, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news

What came next

1. Oct 28, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On October 28, 2026, Actuate Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock (the “Common Stock”) had closed below the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Global Market pursuant to…”
2. Oct 28, 2026Insider · First insider buy since Jun 2025CEO purchased ~$50K of ACTU shares in the open market
3. Oct 30, 20265% stakeHexstone Capital LLC reported a passive stake (13G) of 7.7%

How to read SEC Schedule 13G

A Schedule 13D and a Schedule 13G both disclose beneficial ownership of more than 5% of a US company's voting shares. A 13D is the long form, filed by holders who may seek to influence or control the company, and it must state what they intend to do. A 13G is the short form, open only to passive holders and to certain institutions holding in the ordinary course of business, and it asks no question about intent.

Full guide: Schedule 13D vs Schedule 13G: what is the difference?

What else is on file for Actuate Therapeutics

For Actuate Therapeutics, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ACTU page.

How this filing works

• Schedule 13D vs 13G

Other disclosures at Actuate Therapeutics

• SEC Form 4Oct 29, 2026
• SEC Form 4Jan 7, 2026
• SEC Form 4Jun 30, 2025
• SEC Form 4Jun 30, 2025
• SEC Form 4Jun 30, 2025

Everything OQRO holds on this company is on its ACTU page.